Physician profile
Vicky L Johnson
NPI 1396116034
$2,006.43
in general payments reported to CMS, 2019-2025
23 companies · $666 in 2025
The $666 reported for 2025 was more than what 80% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $67.88 · 2022: $84.48 · 2023: $441 · 2024: $747 · 2025: $666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,854.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,854.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $382.41 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $300.29 | 2021-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $215.67 | 2022-2025 | Airsupra, Farxiga |
| Exact Sciences Corporation | $149.09 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $120.19 | 2021-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Abbvie INC. | $107.29 | 2023-2025 | |
| Amgen INC. | $97.95 | 2023-2025 | Repatha, Otezla, Krystexxa |
| Corcept Therapeutics | $72.23 | 2024-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $70.63 | 2023 | Gvoke Hypopen |
| Dexcom, INC. | $64.67 | 2024-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.55 | 2023-2025 | Jardiance |
| Pfizer INC. | $54.65 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.30 | 2023 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $48.79 | 2021-2025 | |
| Abbott Laboratories | $40.09 | 2024-2025 | Freestyle Libre 3 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $33.65 | 2024 | Veozah |
| Boston Scientific Corporation | $27.41 | 2024 | |
| Inspire Medical Systems, INC. | $23.52 | 2024 | Inspire |
| Horizon Therapeutics Plc | $20.55 | 2023 | Krystexxa |
| Idorsia Pharmaceuticals US INC | $20.13 | 2023 | Quviviq |
| Actelion Pharmaceuticals US, INC. | $16.50 | 2025 | Uptravi, Opsumit |
| Teva Pharmaceuticals USA, INC. | $14.60 | 2025 | Austedo Xr |
| Merck Sharp & Dohme LLC | $13.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vicky Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.